Literature DB >> 11159913

Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

D J Richard1, V Schumacher, B Royer-Pokora, S G Roberts.   

Abstract

The Wilms' tumor suppressor protein WT1 is a transcriptional regulator involved in differentiation and the regulation of cell growth. WT1 is subject to alternative splicing, one isoform including a 17-amino acid region that is specific to mammals. The function of this 17-amino acid insertion is not clear, however. Here, we describe a transcriptional activation domain in WT1 that is specific to the WT1 splice isoform that contains the 17-amino acid insertion. We show that the function of this domain in transcriptional activation is dependent on a specific interaction with the prostate apoptosis response factor par4. A mutation in WT1 found in Wilms' tumor disturbs the interaction with par4 and disrupts the function of the activation domain. Analysis of WT1 derivatives in cells treated to induce par4 expression showed a strong correlation between the transcription function of the WT1 17-amino acid insertion and the ability of WT1 to regulate cell survival and proliferation. Our results provide a molecular mechanism by which alternative splicing of WT1 can regulate cell growth in development and disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159913      PMCID: PMC312625          DOI: 10.1101/gad.185901

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  52 in total

1.  Transactivation of the WT1 antisense promoter is unique to the WT1[+/-] isoform.

Authors:  K Moorwood; A Salpekar; S M Ivins; J Hall; R M Powlesland; K W Brown; K Malik
Journal:  FEBS Lett       Date:  1999-07-30       Impact factor: 4.124

Review 2.  Mechanisms of action of transcription activation and repression domains.

Authors:  S G Roberts
Journal:  Cell Mol Life Sci       Date:  2000-08       Impact factor: 9.261

3.  Binding of general transcription factor TFIIB to an acidic activating region.

Authors:  Y S Lin; I Ha; E Maldonado; D Reinberg; M R Green
Journal:  Nature       Date:  1991-10-10       Impact factor: 49.962

Review 4.  WT1--more than a transcription factor?

Authors:  C Englert
Journal:  Trends Biochem Sci       Date:  1998-10       Impact factor: 13.807

5.  Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.

Authors:  A L Menke; A Shvarts; N Riteco; R C van Ham; A J van der Eb; A G Jochemsen
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

6.  Mutation analysis of the WT1 gene in sporadic childhood leukaemia.

Authors:  E Algar; D Blackburn; T Kromykh; G Taylor; P Smith
Journal:  Leukemia       Date:  1997-01       Impact factor: 11.528

7.  Software and database for the analysis of mutations in the human WT1 gene.

Authors:  C Jeanpierre; C Béroud; P Niaudet; C Junien
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

8.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

Authors:  I A Drummond; S L Madden; P Rohwer-Nutter; G I Bell; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

9.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.

Authors:  K Martin; D Trouche; C Hagemeier; T S Sørensen; N B La Thangue; T Kouzarides
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

10.  The evolution of WT1 sequence and expression pattern in the vertebrates.

Authors:  J Kent; A M Coriat; P T Sharpe; N D Hastie; V van Heyningen
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

View more
  25 in total

Review 1.  Transcriptional mechanisms regulating Ca(2+) homeostasis.

Authors:  Michael F Ritchie; Yandong Zhou; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2010-11-13       Impact factor: 6.817

2.  AHR regulates WT1 genetic programming during murine nephrogenesis.

Authors:  M Hadi Falahatpisheh; Adrian Nanez; Kenneth S Ramos
Journal:  Mol Med       Date:  2011-08-18       Impact factor: 6.354

3.  HtrA2, taming the oncogenic activities of WT1.

Authors:  Jörg Hartkamp; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

4.  A mammal-specific exon of WT1 is not required for development or fertility.

Authors:  Thomas A Natoli; Alice McDonald; Julia A Alberta; Mary E Taglienti; David E Housman; Jordan A Kreidberg
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

5.  Tumour-suppression activity of the proapoptotic regulator Par4.

Authors:  Isabel García-Cao; Angeles Duran; Manuel Collado; Maria J Carrascosa; Juan Martín-Caballero; Juana M Flores; Maria T Diaz-Meco; Jorge Moscat; Manuel Serrano
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807

6.  Mice lacking the 68-amino-acid, mammal-specific N-terminal extension of WT1 develop normally and are fertile.

Authors:  Colin G Miles; Joan Slight; Lee Spraggon; Maureen O'Sullivan; Charles Patek; Nicholas D Hastie
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.

Authors:  Jörg Hartkamp; Brian Carpenter; Stefan G E Roberts
Journal:  Mol Cell       Date:  2010-01-29       Impact factor: 17.970

8.  Par-4: a new activator of myosin phosphatase.

Authors:  Susanne Vetterkind; Eunhee Lee; Eric Sundberg; Ransom H Poythress; Terence C Tao; Ute Preuss; Kathleen G Morgan
Journal:  Mol Biol Cell       Date:  2010-02-03       Impact factor: 4.138

9.  ZIP kinase triggers apoptosis from nuclear PML oncogenic domains.

Authors:  Taro Kawai; Shizuo Akira; John C Reed
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

10.  Predicting functional alternative splicing by measuring RNA selection pressure from multigenome alignments.

Authors:  Hongchao Lu; Lan Lin; Seiko Sato; Yi Xing; Christopher J Lee
Journal:  PLoS Comput Biol       Date:  2009-12-18       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.